1.59




FIGURE 1




FIGURE 2




FIGURE 3

4 / 5 9








FIGURE 4




weeks after start of treatment








months after start of treatment



weeks after start of treatment



months after start of treatment

A 15 NR II BIDNR 🕇 C 3a RR F 16 PR Anti-E2 levels in INCOMPLETE responders to IFN treatment 50 45 40 35 SERIES 2 30 25 20 15 10 2 S/N 8 2 0 FIGURE 11






FIGURE 13




13 59


FIGURE 14


Competition of reactivity of anti-E1 Mabs with peptides





<u>q</u> ₩ 0 3a 1 lb q ط Anti-E1 (epitope 1) levels in RESPONDERS to IFN treatment 80 75 70 65 9 55 20 weeks after start of treatment 30 35 40 45 SERIES 1 25 20 15 10 2 0 Ś N/S 8 9 0 7 0









FIGURE 20



21/59 Figure 21

GGCATGCAAGCTTAATTAATT3' (SEQ ID NO 1) 3'ACGTCCGTACGTTCGAATTAATTAATCGA5' (SEQ ID NO 94)

÷

5'CCGGGGAGGCCTGCACGTGATCGAGGGCAGACACCATCACCACCATCACTAATAGT TAATTAACTGCA 3' (SEQ ID NO 2)

5' (SEQ ID NO 95)

SEC ID NO 3 (HCCI9A)

ATGCCCGGTTGCTCTTTCTCTATCTTCCTCTTGGCTTTACTGTCCTGTCTGACCATTCCA CCAACTCAAGCATTGTGTATGAGGCAGCGGACATGATCATGCACACCCCGGGTGCGT GCCCTGCGTTCGGGAGACAACTCTTCCCGCTGCTGGGTAGCGCTCACCCCACGCTC GCAGCTAGGAACGCCAGCGTCCCCACCACGACAATACGACGCCACGTCGATTTGCTCG TTGGGGCGCTGCTCTGTTCCGCTATGTACGTGGGGGATCTCTGCGGATCTGTCTTC CTCGTCTCCCAGCTGTTCACCATCTCGCCTCGCCGGCATGAGACGGTGCAGGACTGCA ATTGCTCAATCTATCCCGGCCACATAACAGGTCACCGTATGGCTTGGGATATGATGAT GAACTGGTCGCCTACAACGGCCCTGGTGGTATCGCAGCTGCTCCGGATCCCACAAGCT GTCGTGGACATGGTGGCGGGGCCCATTGGGGAGTCCTGGCGGGCCTCGCCTACTATT CCATGGTGGGGAACTGGGCTAAGGTTTTGATTGTGATGCTACTCTTTGCTCTCTAATAG

SEQ ID NO 5 (HCCI10A)

ATGTTGGGTAAGGTCATCGATACCCTTACATGCGGCTTCGCCGACCTCGTGGGGTACA TTCCGCTCGTCGGCGCCCCCTAGGGGGCGCTGCCAGGGCCCTGGCGCATGGCGTCCG GGTTCTGGAGGACGGCGTGAACTATGCAACAGGGAATTTGCCCGGTTGCTCTTTCTCT ATCTTCCTCTTGGCTTTGCTGTCCTGTCTGACCGTTCCAGCTTCCGCTTATGAAGTGCG CAACGTGTCCGGGATGTACCATGTCACGAACGACTGCTCCAACTCAAGCATTGTGTAT GAGGCAGCGGACATGATCATGCACACCCCGGGTGCGTGCCCTGCGTTCGGGAGAAC AACTCTTCCCGCTGCTGGGTAGCGCTCACCCCCACGCTCGCAGCTAGGAACGCCAGCG TCCCCACCACGACAATACGACGCCACGTCGATTTGCTCGTTGGGGCGGCTGCTTTCTG

WO 96/04385 PCT/EP95/03031

22/59

SEQ ID NO 7 (HCCI11A)

SEQ ID NO 9 (HCCI12A)

SEQ ID NO 11 (HCCI13A)

 GCCCTGCGTTCGGGAGGGCAACTCCTCCCGTTGCTGGGTGGCGCTCACTCCCACGCTC
GCGGCCAGGAACGCCAGCGTCCCCACAACGACAATACGACGCCACGTCGATTTGCTC
GTTGGGGCTGCTTTCTGTTCCGCTATGTACGTGGGGGATCTCTGTTTT
CCTTGTTTCCCAGCTGTTCACCTTCTCACCTCGCCGGCATCAAACAGTACAGGACTGCA
ACTGCTCAATCTATCCCGGCCATGTATCAGGTCACCGCATGGCTTGGGATATGATGAT
GAACTGGTAATAG

SEQ ID NO 13 (HCCI17A)

SEQ ID NO 15 (HCPr51)
ATGCCCGGTTGCTCTTTCTCTATCTT

SEQ ID NO 16 (HCPr52)
ATGTTGGGTAAGGTCATCGATACCCT

SEQ ID NO 17 (HCPr53)
CTATTAGGACCAGTTCATCATCATATCCCA

SEQ ID NO 18 (HCPr54)
CTATTACCAGTTCATCATCATATCCCA

SEQ ID NO 19 (HCPr107)

ATACGACGCCACGTCGATTCCCAGCTGTTCACCATC

WO 96/04385 PCT/EP95/03031

SEQ ID NO 20 (HCPr108)

GATGGTGAACAGCTGGGGAATCGACGTGGCGTCGTAT

SEQ ID NO 21 (HCCI37)

SEQ ID NO 23 (HCCI38)

SEQ ID NO 25 (HCC139)

ATGTTGGGTAAGGTCATCGATACCCTTACATGCGGCTTCGCCGACCTCGTGGGGTACA
TTCCGCTCGTCGGCGCCCCCCTAGGGGGCGCTGCCAGGGCCCTGGCGCATGCCTCCG
GGTTCTGGAGGACGGCGTGAACTATGCAACAGGGAATTTGCCCGGTTGCTCTTTCTCT

ATCTTCCTCTTGGCTTTGCTGTCCTGTCTGACCGTTCCAGCTTCCGCTTATGAAGTGCG
CAACGTGTCCGGGATGTACCATGTCACGAACGACTGCTCCAACTCAAGCATTGTGTAT
GAGGCAGCGGACATGATCATGCACACCCCCGGGTGCCCTGCGTTCGGGAGAAC
AACTCTTCCCGCTGCTGGGTAGCGCTCACCCCCACGCTCGCAGCTAGGAACGCCAGCG
TCCCCACCACGACAATACGACGCCACGTCGATTCCCAGCTGTTCACCATCTCGCCTCG
CCGGCATGAGACGGTGCAGGACTGCAATTGCTCAATCTATCCCGGCCACATAACGGGT
CACCGTATGGCTTGGGATATGATGATGAACTGGTCGCCTACAACGGCCCTGGTGGTAT
CGCAGCTGCTCCGGATCCTCTAATAG

SEQ ID NO 27 (HCCI40)

SEQ ID NO 29 (HCC162)

ATGGGTAAGGTCATCGATACCCTTACGTGCGGATCTCATGGGGTACATCC
CGCTCGTCGGCGCTCCCGTAGGAGGCGTCGCAAGAGCCCTTGCGCATGGCGTGAGGGC
CCTTGAAGACGGGATAAATTTCGCAACAGGGAATTTGCCCGGTTGCTCCTTTTCTATTT
TCCTTCTCGCTCTGTTCTCTTGCTTAATTCATCCAGCAGCTAGTCTAGAGTGGCGGAAT
ACGTCTGGCCTCTATGTCCTTACCAACGACTGTTCCAATAGCAGTATTGTGTACGAGGC
CGATGACGTTATTCTGCACACACCCGGCTGCATACCTTGTGTCCAGGACGGCAATACA
TCCACGTGCTGGACCCCAGTGACACCTACAGTGGCAGTCAAGTACGTCGGAGCAACCA
CCGCTTCGATACGCAGTCATGTGGACCTATTAGTGGGCGCGGCCACGATGTGCTCTGC
GCTCTACGTGGGTGACATGTGTGGGGCTGTCTTCCTCGTGGGACAAGCCTTCACGTTCA
GACCTCGTCGCCATCAAACGGTCCAGACCTGTAACTGCTCGCTGTACCCAGGCCATCT
TTCAGGACATCGAATGGCTTGGGGATATGATGATGATGATGATAAG

SEQ ID NO 31 (HCCl63)

ATGGGTAAGGTCATCGATACCCTAACGTGCGGATTCGCCGATCTCATGGGGTATATCC
CGCTCGTAGGCGGCCCCATTGGGGGGCGTCGCAAGGGCTCTCGCACACGGTGTGAGGGT
CCTTGAGGACGGGGTAAACTATGCAACAGGGAATTTACCCGGTTGCTCTTTCTCTATCT
TTATTCTTGCTCTTCTCTCGTGTCTGACCGTTCCGGCCTCTGCAGTTCCCTACCGAAATG
CCTCTGGGATTTATCATGTTACCAATGATTGCCCAAACTCTTCCATAGTCTATGAGGCA
GATAACCTGATCCTACACGCACCTGGTTGCGTGCCTTGTGTCATGACAGGTAATGTGA
GTAGATGCTGGGTCCAAATTACCCCTACACTGTCAGCCCCGAGCCTCGGAGCAGTCAC
GGCTCCTCTTCGGAGAGCCGTTGACTACCTAGCGGGAGGGGCTGCCCTCTGCTCCGCG
TTATACGTAGGAGACGCGTTGGGGACACTATTCTTGGTAGGCCAAATGTTCACCTATA
GGCCTCGCCAGCACGCTACGGTGCAGAACTGCAACTGTTCCATTTACAGTGGCCATGT
TACCGGCCACCGGATGGCATGGGATATGATGATGAACTGGTAATAG

SEQ ID NO 33 (HCPr109)
TGGGATATGATGATGAACTGGTC

SEQ ID NO 34 (HCPr72)

CTATTATGGTGGTAAKGCCARCARGAGCAGGAG

SEQ ID NO 35 (HCCL22A)

SEQ ID NO 37 (HCCI41)

GATCCCACAAGCTGTCGTGGACATGGTGGCGGGGGCCCATTGGGGAGTCCTGGCGG CCTCGCCTACTATTCCATGGTGGGGAACTGGGCTAAGGTTTTGGTTGATGCTACTCT TTGCCGGCGTCGACGGGCATACCGGCGTGTCAGGAGGGGCAGCAGCCTCCGATACCA GGGGCCTTGTGTCCCTCTTTAGCCCCGGGTCGGCTCAGAAATCCAGCTCGTAAACAC AGGGTTCTTTGCCGCACTATTCTACAAACACAAATTCAACTCGTCTGGATGCCCAGAG CGCTTGGCCAGCTGTCGCTCATCGACAAGTTCGCTCAGGGGTGGGGTCCCCTCACTT ACACTGAGCCTAACAGCTCGGACCAGAGGCCCTACTGCTGGCACTACGCGCCTCGACC GTGTGGTATTGTACCCGCGTCTCAGGTGTGCGGTCCAGTGTATTGCTTCACCCCGAGCC CGACTCGGATGTGCTGATTCTCAACACGCGGCGGCGCGCGGGGGCAACTGGTTCGGC TGTACATGGATGAATGGCACTGGGTTCACCAAGACGTGTGGGGGCCCCCCGTGCAACA CGAGGCCACCTACGCCAGATGCGGTTCTGGGCCCTGGCTGACACCTAGGTGTATGGTT CATTACCCATATAGGCTCTGGCACTACCCCTGCACTGTCAACTTCACCATCTTCAAGGT TAGGATGTACGTGGGGGGGGGGGGAGCACAGGTTCGAAGCCGCATGCAATTGGACTCG AGGAGAGCGTTGTGACTTGGAGGACAGGGATAGATCAGAGCTTAGCCCGCTGCTGCTG TCTACAACAGAGTGGCAGAGTGAGCTTAATTAATTAG

SEQ ID NO 39 (HCC142)

GATCCCACAAGCTGTCGTGGACATGGTGGCGGGGGCCCATTGGGGAGTCCTGGCGGG CCTCGCCTACTATTCCATGGTGGGGAACTGGGCTAAGGTTTTGGTTGTGATGCTACTCT

PCT/EP95/03031

TTGCCGGCGTCGACGGGCATACCCGCGTGTCAGGAGGGGCAGCAGCCTCCGATACCA GGGGCCTTGTGTCCCTCTTTAGCCCCGGGTCGGCTCAGAAAATCCAGCTCGTAAACAC AGGGTTCTTTGCCGCACTATTCTACAAACACAAATTCAACTCGTCTGGATGCCCAGAG CGCTTGGCCAGCTGTCGCTCCATCGACAAGTTCGCTCAGGGGTGGGGTCCCCTCACTT ACACTGAGCCTAACAGCTCGGACCAGAGGCCCTACTGCTGGCACTACGCGCCTCGACC GTGTGGTATTGTACCCGCGTCTCAGGTGTGCGGTCCAGTGTATTGCTTCACCCCGAGCC CGACTCGGATGTGCTGATTCTCAACAACACGCGGCGCCGCGAGGCAACTGGTTCGGC TGTACATGGATGAATGGCACTGGGTTCACCAAGACGTGTGGGGGCCCCCCGTGCAACA CGAGGCCACCTACGCCAGATGCGGTTCTGGGCCCTGGCTGACACCTAGGTGTATGGTT CATTACCCATATAGGCTCTGGCACTACCCCTGCACTGTCAACTTCACCATCTTCAAGGT TAGGATGTACGTGGGGGGCGTGGAGCACAGGTTCGAAGCCGCATGCAATTGGACTCG AGGAGAGCGTTGTGACTTGGAGGACAGGGATAGATCAGAGCTTAGCCCGCTGCTGCTG TCTACAACAGGTGATCGAGGGCAGACACCATCACCACCATCACTAATAG

SEQ ID NO 41 (HCCI43)

ATGGTGGGGAACTGGGCTAAGGTTTTGGTTGTGATGCTACTCTTTGCCGGCGTCGACG GGCATACCCGCGTGTCAGGAGGGGCAGCAGCCTCCGATACCAGGGGCCTTGTGTCCCT CTTTAGCCCCGGGTCGGCTCAGAAATCCAGCTCGTAAACACCAACGGCAGTTGGCAC ATCAACAGGACTGCCCTGAACTGCAACGACTCCCTCCAAACAGGGTTCTTTGCCGCAC TATTCTACAAACACAAATTCAACTCGTCTGGATGCCCAGAGCGCTTGGCCAGCTGTCG CTCCATCGACAAGTTCGCTCAGGGGTGGGGTCCCCTCACTTACACTGAGCCTAACAGC TCGGACCAGAGGCCCTACTGCTGGCACTACGCGCCTCGACCGTGTGGTATTGTACCCG CGTCTCAGGTGTGCGGTCCAGTGTATTGCTTCACCCCGAGCCCTGTTGTGGTGGGGAC GACCGATCGGTTTGGTGTCCCCACGTATAACTGGGGGGCGAACGACTCGGATGTGCTG ATTCTCAACAACACGCGGCCGCCGCGAGGCAACTGGTTCGGCTGTACATGGATGAATG GCACTGGGTTCACCAAGACGTGTGGGGGGCCCCCCGTGCAACATCGGGGGGGCCGGCA ACAACACCTTGACCTGCCCCACTGACTGTTTTCGGAAGCACCCCGAGGCCACCTACGC CAGATGCGGTTCTGGGCCCTGGCTGACACCTAGGTGTATGGTTCATTACCCATATAGG CTCTGGCACTACCCCTGCACTGTCAACTTCACCATCTTCAAGGTTAGGATGTACGTGGG GGGCGTGGAGCACAGGTTCGAAGCCGCATGCAATTGGACTCGAGGAGAGCGTTGTGA CTTGGAGGACAGGGATAGATCAGAGCTTAGCCCGCTGCTGTCTACAACAGAGTGG CAGAGCTTAATTAATTAG

ATGGTGGGGAACTGGGCTAAGGTTTTGGTTGTGATGCTACTCTTTGCCGGCGTCGACG GGCATACCCGCGTGTCAGGAGGGGCAGCAGCCTCCGATACCAGGGGCCTTGTGTCCCT CTTTAGCCCCGGGTCGGCTCAGAAAATCCAGCTCGTAAACACCAACGGCAGTTGGCAC ATCAACAGGACTGCCCTGAACTGCAACGACTCCCTCCAAACAGGGTTCTTTGCCGCAC TATTCTACAAACACAAATTCAACTCGTCTGGATGCCCAGAGCGCTTGGCCAGCTGTCG CTCCATCGACAAGTTCGCTGAGGGGTGGGGTCCCCTCACTTACACTGAGCCTAACAGC TCGGACCAGAGGCCCTACTGCTGGCACTACGCGCCTCGACCGTGTGGTATTGTACCCG CGTCTCAGGTGTGCGGTCCAGTGTATTGCTTCACCCCGAGCCCTGTTGTGGTGGGGAC ATTCTCAACAACACGCGGCGCCGCGAGGCAACTGGTTCGGCTGTACATGGATGAATG GCACTGGGTTCACCAAGACGTGTGGGGGGCCCCCCGTGCAACATCGGGGGGGCCGGCA ACAACACCTTGACCTGCCCCACTGACTGTTTTCGGAAGCACCCCGAGGCCACCTACGC CAGATGCGGTTCTGGGCCCTGGCTGACACCTAGGTGTATGGTTCATTACCCATATAGG CTCTGGCACTACCCCTGCACTGTCAACTTCACCATCTTCAAGGTTAGGATGTACGTGGG GGGCGTGGAGCACAGGTTCGAAGCCGCATGCAATTGGACTCGAGGAGAGCGTTGTGA CTTGGAGGACAGGGATAGATCAGAGCTTAGCCCGCTGCTGCTGTCTACAACAGGTGAT CGAGGGCAGACCACCACCACCACCATCACTAATAG

SEQ ID NO 45 (HCCL64)

SEQ ID NO 47 (HCC165)

AATTTGGGTAAGGTCATCGATACCCTTACATGCGGCTTCGCCGACCTCGTGGGGTACA TTCCGCTCGTCGGCGCCCCCTAGGGGGCGCTGCCAGGGCCCTGGCGCATGGCGTCCG GGTTCTGGAGGACGGCGTGAACTATGCAACAGGGAATTTGCCCGGTTGCTCTTTCTCT ATCTTCCTCTTGGCTTTGCTGTCCTGTCTGACCGTTCCAGCTTCCGCTTATGAAGTGCG CAACGTGTCCGGGATGTACCATGTCACGAACGACTGCTCCAACTCAAGCATTGTGTAT GAGGCAGCGGACATGATCATGCACACCCCGGGTGCGTGCCCTGCGTTCGGGAGAAC AACTCTTCCCGCTGCTGGGTAGCGCTCACCCCCACGCTCGCAGCTAGGAACGCCAGCG TCCCCACCACGACAATACGACGCCACGTCGATTTGCTCGTTGGGGGCGGCTGCTTTCTG TTCCGCTATGTACGTGGGGACCTCTGCGGATCTGTCTTCCTCGTCTCCCAGCTGTTCA CCATCTCGCCTCGCCGGCATGAGACGGTGCAGGACTGCAATTGCTCAATCTATCCCGG CCACATAACGGGTCACCGTATGGCTTGGGATATGATGATGAACTGGTCGCCTACAACG GCCCTGGTGGTATCGCAGCTGCTCCGGATCCCACAAGCTGTCGTGGACATGGTGGCGG GGGCCCATTGGGGAGTCCTGGCGGGCCTCGCCTACTATTCCATGGTGGGGAACTGGGC TAAGGTTTTGGTTGTGATGCTACTCTTTGCCGGCGTCGACGGGCATACCCGCGTGTCAG GAGGGGCAGCCTCCGATACCAGGGGCCTTGTGTCCCTCTTTAGCCCCGGGTCGGC TCAGAAAATCCAGCTCGTAAACACCAACGGCAGTTGGCACATCAACAGGACTGCCCT GAACTGCAACGACTCCCCAAACAGGGTTCTTTGCCGCACTATTCTACAAACACAAA TTCAACTCGTCTGGATGCCCAGAGCGCTTGGCCAGCTGTCGCTCCATCGACAAGTTCG CTCAGGGGTGGGGTCCCCTCACTTACACTGAGCCTAACAGCTCGGACCAGAGGCCCTA CTGCTGGCACTACGCGCCTCGACCGTGTGGTATTGTACCCGCGTCTCAGGTGTGCGGT CCAGTGTATTGCTTCACCCCGAGCCCTGTTGTGGTGGGGGACGACCGATCGGTTTGGTGT CCCCACGTATAACTGGGGGGGGAACGACTCGGATGTGCTGATTCTCAACACACGCGG CCGCCGCGAGGCAACTGGTTCGGCTGTACATGGATGAATGGCACTGGGTTCACCAAGA CGTGTGGGGGCCCCCCGTGCAACATCGGGGGGGGCCGGCAACACACCTTGACCTGCC

SEQ ID NO 49 (HCCI66)


ATGAGCACGAATCCTAAACCTCAAAGAAAAACCAAACGTAACACCAACCGCCGCCCA CAGGACGTCAAGTTCCCGGGCGGTGGTCAGATCGTTGGTGGAGTTTACCTGTTGCCGC GCAGGGGCCCAGGTTGGGTGTGCGCGCGACTAGGAAGACTTCCGAGCGGTCGCAAC CTCGTGGGAGGCGACAACCTATCCCCAAGGCTCGCCGACCCGAGGGTAGGGCCTGGG CTCAGCCGGGTACCCTTGGCCCCTCTATGGCAATGAGGGCATGGGGTGGGCAGGATG GCTCCTGTCACCCGGGGCTCTCGGCCTAGTTGGGGCCCTACAGACCCCGGGGTAGG TCGCGTAATTTGGGTAAGGTCATCGATACCCTTACATGCGGCTTCGCCGACCTCGTGG GGTACATTCCGCTCGTCGGCGCCCCCCTAGGGGGCGCTGCCAGGGCCCTGGCGCATGG CGTCCGGGTTCTGGAGGACGGCGTGAACTATGCAACAGGGAATTTGCCCGGTTGCTCT TTCTCTATCTTCCTCTTGGCTTTGCTGTCCTGTCTGACCGTTCCAGCTTCCGCTTATGAA GTGCGCAACGTGTCCGGGATGTACCATGTCACGAACGACTGCTCCAACTCAAGCATTG GAACAACTCTTCCCGCTGCTGGGTAGCGCTCACCCCCACGCTCGCAGCTAGGAACGCC AGCGTCCCACCACGACAATACGACGCCACGTCGATTTGCTCGTTGGGGCGGCTGCTT TCTGTTCCGCTATGTACGTGGGGGACCTCTGCGGATCTGTCTTCCTCGTCTCCCAGCTG TTCACCATCTCGCCTCGCCGGCATGAGACGGTGCAGGACTGCAATTGCTCAATCTATC CCGGCCACATAACGGGTCACCGTATGGCTTGGGATATGATGATGAACTGGTCGCCTAC AACGGCCCTGGTGGTATCGCAGCTGCTCCGGATCCCACAAGCTGTCGTGGACATGGTG GCGGGGCCCATTGGGGAGTCCTGGCGGGCCTCGCCTACTATTCCATGGTGGGGAACT GGGCTAAGGTTTTGGTTGTGATGCTACTCTTTGCCGGCGTCGACGGGCATACCCGCGT GTCAGGAGGGGCAGCAGCCTCCGATACCAGGGGCCTTGTGTCCCTCTTTAGCCCCGGG

TCGGCTCAGAAATCCAGCTCGTAAACACCAACGGCAGTTGGCACATCAACAGGACT GCCCTGAACTGCAACGACTCCCCAAACAGGGTTCTTTGCCGCACTATTCTACAAAC ACAAATTCAACTCGTCTGGATGCCCAGAGCGCTTGGCCAGCTGTCGCTCCATCGACAA GTTCGCTCAGGGGTGGGGTCCCCTCACTTACACTGAGCCTAACAGCTCGGACCAGAGG CCCTACTGCTGGCACTACGCGCCTCGACCGTGTGGTATTGTACCCGCGTCTCAGGTGT GCGGTCCAGTGTATTGCTTCACCCCGAGCCCTGTTGTGGTGGGGACGACCGATCGGTT TGGTGTCCCCACGTATAACTGGGGGGGGGAACGACTCGGATGTGCTGATTCTCAACAAC ACGCGGCCGCGAGGCAACTGGTTCGGCTGTACATGGATGAATGGCACTGGGTTCA CCAAGACGTGTGGGGGCCCCCCGTGCAACATCGGGGGGGCCGGCAACACACCTTGA CCTGCCCACTGACTGTTTTCGGAAGCACCCCGAGGCCACCTACGCCAGATGCGGTTC TGGGCCCTGGCTGACACCTAGGTGTATGGTTCATTACCCATATAGGCTCTGGCACTAC CCCTGCACTGTCAACTTCACCATCTTCAAGGTTAGGATGTACGTGGGGGGGCGTGGAGC ACAGGTTCGAAGCCGCATGCAATTGGACTCGAGGAGAGCGTTGTGACTTGGAGGACA GGGATAGATCAGAGCTTAGCCCGCTGCTGTCTACAACAGAGTGGCAGATACTGCC CTGTTCCTTCACCACCCTGCCGGCCCTATCCACCGGCCTGATCCACCTCCATCAGAAC ATCGTGGACGTGCAATACCTGTACGGTGTAGGGTCGGCGGTTGTCTCCCTTGTCATCA AATGGGAGTATGTCCTGTTGCTCTTCCTCTGGCAGACGCGCGCATCTGCGCCTGC TTATGGATGATGCTGCTGATASCTCAAGCTGAGGCCGCCTTAGAGAACCTGGTGGTCC TCAATGCGGCGGCCGTGGCCGGGGCGCATGGCACTCTTTCCTTGTGTTCTTCTGT GCTGCCTGGTACATCAAGGGCAGGCTGGTCCCTGGTGCGGCATACGCCTTCTATGGCG TGTGGCCGCTGCTCCTGCTTGCTGGCCTTACCACCACGAGCTTATGCCTAGTAA

Figure 22

OD measured at 450 nm construct

Fraction volume	dilution	39 Type Ib	40 Type Ih	62 Туре 3a	63 Type 5a
START 23 ml FLOW THROUGH 23 1 0.4 ml 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	1/20 3 ml 1/20 1/200	2.5:7 0.057 0.102 0.396 2.627 3 2.694 2.408 2.176 1.461 1.286 0.981 0.812 0.373 0.653 0.441 0.321 0.525 0.351 0.192	1.954 0.085 0.051 0.550 2.603 2.967 2.810 2.499 2.481 1.970 1.422 0.926 0.781 0.650 0.432 0.371 0.348 0.374 0.186 0.171 0.164	1 426 0.176 0.048 0.090 2.481 3 2.640 1.359 0.347 1.624 0.887 0.543 0.294 0.239 0.145 0.151 0.098 0.099 0.083 0.084	1.142 0.120 0.050 0.057 2.372 2.694 2.154 1.561 1.390 0.865 0.604 0.519 0.294 0.199 0.209 0.184 0.151 0.106 0.108 0.090 0.087



35/59 Figure 24

volumo	dilution	OD measured at 450 nm construct					
voidine	dildtion	Type	Type	Type	63 Type		
		10	16	3a 	5a 		
250 <i>µ</i> l	1/200	0 072	0.130	0 096	0 051		
					0.052		
					0 052		
					0 054 0.056		
					0.039		
					0 066		
		3		2 528	0 889		
		3		3	2.345		
				2 849	2.580		
				1 424	1.333		
					0.162		
					0.064		
					0.057 0.051		
					0.046		
					0.040		
		0 045			0 048		
		0 046	0.048	0.047	0 057		
		0 045	0.048	0 050	0.057		
		0 046	0.049	0 048	0 049		
	volume 250 µl		volume dilution 39 Type 1b 250 \(\mu \) 1/200 0 072 0.109 0.279 0.093 0.080 0.251 3 3 3 2.227 0.263 0.071 0.103 0.045 0.045 0.045 0.045 0.045 0.045 0.045	volume dilution 39 40 Type Type 1b 1b 250 \(\mu \) 1/200 0.072 0.130 0.109 0.293 0.279 0.249 0.093 0.151 0.080 0.266 0.251 0.100 3 1.649 3 3 3 3 3 3 2.227 1.921 0.263 0.415 0.071 0.172 0.103 0.054 0.045 0.045 0.045 0.045 0.045 0.045 0.045 0.048 0.045 0.048 0.045 0.048	volume dilution 39 / Type / 1b Type / 1b 250 μl 1/200 0.072 / 0.130 / 0.096 / 0.293 / 0.084 / 0.279 / 0.249 / 0.172 / 0.093 / 0.151 / 0.297 / 0.080 / 0.256 / 0.438 / 0.251 / 0.100 / 0.457 / 3 / 1.649 / 0.722 / 3 / 3 / 1.649 / 0.722 / 3 / 3 / 3 / 2.528 / 3 / 3 / 3 / 2.528 / 3 / 3 / 3 / 2.528 / 3 / 3 / 3 / 2.528 / 3 / 3 / 3 / 2.528 / 3 / 3 / 3 / 2.528 / 3 / 3 / 3 / 3 / 2.528 / 3 / 3 / 3 / 3 / 2.528 / 3 / 3 / 3 / 3 / 3 / 3 / 3 / 3 / 3 /		




FIGURE 25




Figure 25




Figure 27





Figure 28

WO 96/02385 PCT/ΣΡ95/03031



Lane 1: Crude Lysate

Lane 2: Flow through Lentil Chromatography

Lanc 3: Wash with EMPIGEN Lentil Chromatography

Lanc 4: Eluate Lentil Chromatography

Lane 5: Flow through during concentration lental cluate

Lanc of Pool of Flatter Size Exclusion Chromatography

Figure 29: Western Blot Analysis with anti-E1 mouse monoclonal 5E1A10

41/59





FIGURE 30

A: NON - REDUCED






FIGURE 31

0.1





FIGURE 32

0.5


FIGURE 33: SILVER STAIN OF PURIFIED E2



- 1. 30 mM IMIDAZOLE WASH NI-IMAC
- 2. 05 us E2

WO 96/94385 PCT/EP95/03031

45 59 Figure 34



No.	Ret.	Peak start (ml)	Peak end (ml)	Dur (ml)	Area (ml*mAU)	Height (mAU)
1	-0.45	-0.46	-0.43	0.04	0.0976	4,579
2	1.55	0.75	3.26	2.51	796.4167	889.377
3	3.27	3.26	3.31	0.05	0.0067	0.224
4	3.33	3.32	3.33	0.02	0.0002	0.018

Total number of detected peaks = 4


Total Area above baseline = 0.796522 ml*AU

Total area in evaluated peaks = 0.796521 ml*AU

Ratio peak area / total area = 0.999999


Total peak duration = 2.613583 ml

FIGURE 35A




47/59

FIGURE 35B



Eigure 36

E1 Ab






FIGURE 37





Figure 38

Relative Map Positions of anti-E2 monoclonal antibodies






Figure 39




Figure 40

WO 96/04385


EIGly-5

98

85

E1Gly-1²⁵ EIGly-3 E1G1y-4 EIGly-2 1:2 In Vitro Mutagenesis of HCV ELglycoprotein Total Control CORE 82 83 84 $\frac{\infty}{2}$

30 cycles (1 min at 95°C; 1 min at 50°C; 1 min at 72°C) In Vitro Mutagenesis of HCV E1 glycoprotein First step of PCR amplification (Gly-# and Ovr-# primers) BamILL 0VR-# **₹**\$\$ \$ 5 #-JAO GLY-# EcoR.1 GPT CPT 1 Fig. 42A



E1Gly-2 EIGly-3 E1Gly-4 EIGly-1 EIGly-5 E2 ΥĘ In Vitro Mutagenesis of HCV E1 glycoprotein OVR.6 Bantl 550 at Bamll 1 6.30 n.t **⊙**-|¥ 770 m 078.4 OVR-J ⊕-|₹ 770 111 CORE Fig. 43 10A 82 83 84 85 8 98

		HeLa cells		RK 13 cells		
		2 4 5 7		2 3 5 7 8.		
0.08			— 80,0			80.0
49.5	_		— 49.5			49.5
32.5	- .	Mark Comment	32.5			32.5
27.5			— 27.5			27.5
18.5	_		— 18.5			18.5

Figure 44A




Figure 448






Figure 45



Figure 46